HZ-R078

News alerts, weekly reports and conference planners

Company:

HealZen Therap

Drug class:

STAT3 protein degrader

Related drugs:

‹

KT-333 (2)

›

almost2years

HZ-R078: A tumor-enriched STAT3 degrader for treating T-cell lymphoma in pre-clinical models (AACR 2023)

HZ-R078 is a selective and potent STAT3 degrader which has tumor-enriched distribution character. The pre-clinical efficacy and safety study support its further development in clinical stage for T-cell lymphoma therapy.

almost 2 years ago

Preclinical

STAT3 (Signal Transducer And Activator Of Transcription 3) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • STAT2 (Signal transducer and activator of transcription 2) • STAT4 (Signal Transducer And Activator Of Transcription 4)

HZ-R078